Oxford BioTherapeutics

Oxford BioTherapeutics is a clinical-stage oncology company developing first-in-class antibody-based therapies to improve patient outcomes. Its proprietary proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets and supports the development of antibody-drug conjugates (ADCs), chimeric antigen receptors (CAR-Ts), immuno-oncology antibodies (IOs), radiopharmaceutical and bispecific therapeutic modalities. The company describes a fully integrated discovery and development workflow spanning from target identification to IND-enabling studies, and states a mission to become a key player in the ADC and T-cell engager (TCE) field.

Oxford BioTherapeutics is a clinical-stage oncology company developing first-in-class antibody-based therapies. Its proprietary proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets and supports the development of antibody-drug conjugates (ADCs), chimeric antigen receptors (CAR-Ts), immuno-oncology antibodies (IOs), radiopharmaceutical and bispecific therapeutic modalities. The company states that it continuously enhances its OGAP®-Verify database to accurately represent patient tumours and the tumour microenvironment, and that its fully integrated discovery and development capabilities span from target identification to IND-enabling studies. It describes its mission as becoming a key player in the ADC and T-cell engager (TCE) field.

Clinical-stage oncology company developing first-in-class antibody-based therapies; aims to become a key player in the ADC and T-cell engager field.

• OGAP®-Verify

  Proprietary, high-sensitivity proteomic target discovery platform specialising in identifying novel membrane-based protein targets.

1. 1Developing First-in-Class Cancer Therapies | Oxford BioTherapeuticsoxfordbiotherapeutics.com
2. 2About Us | Oxford BioTherapeuticsoxfordbiotherapeutics.com
3. 3Oxford Biotherapeutics (United Kingdom)wikidata.org